Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy With DBV712 250 mcg in 1-through 3-year-old Children With Peanut Allergy

NCT07003919 is registered in ClinicalTrials.gov with DBV Technologies as lead sponsor.

NCT NCT07003919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07003919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy With DBV712 250 mcg in 1-through 3-year-old Children With Peanut Allergy
Lead sponsor
DBV Technologies
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 24, 2025
Completion date
May 31, 2028
Enrollment
480 (estimated)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

allergy, peanut allergy